FDA to Convene Pharmacy Compounding Advisory Committee in July FDA Peptide Reclassification 2026: What Researchers Want This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of